Ventyx's stock soars on cardiovascular data for NLRP3 drug

Kyle LaHucik

Biotech Correspondent

Ventyx Biosciences’ Phase 2 data showed a significant reduction in cardiovascular risks in patients with obesity through NLRP3 inhibition, a closely-watched target in neurologic and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Ventyx's stock soars on cardiovascular data for NLRP3 drug

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

Drugmakers push to break ground after Trump's 100% tariff threat

Mikael Dolsten, Craig Crews team up for new molecular glue biotech

Are recent strides in neurology R&D enough to make it a hot M&A target?

FDA provides new checklists to prevent drug submission delays

Tango to advance pancreatic cancer drug into Phase 3, raises $225M

The advent of digital therapeutics and what it means for healthcare

Ven­tyx's stock soars on car­dio­vas­cu­lar da­ta for NL­RP3 drug

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

Drug­mak­ers push to break ground af­ter Trump's 100% tar­iff threat

Mikael Dol­sten, Craig Crews team up for new mol­e­c­u­lar glue biotech

Are re­cent strides in neu­rol­o­gy R&D enough to make it a hot M&A tar­get?

FDA pro­vides new check­lists to pre­vent drug sub­mis­sion de­lays

Tan­go to ad­vance pan­cre­at­ic can­cer drug in­to Phase 3, rais­es $225M

The ad­vent of dig­i­tal ther­a­peu­tics and what it means for health­care

Ventyx's stock soars on cardiovascular data for NLRP3 drug

Drugmakers push to break ground after Trump's 100% tariff threat

Mikael Dolsten, Craig Crews team up for new molecular glue biotech

Are recent strides in neurology R&D enough to make it a hot M&A target?

FDA provides new checklists to prevent drug submission delays

Tango to advance pancreatic cancer drug into Phase 3, raises $225M

The advent of digital therapeutics and what it means for healthcare